Effect of losartan on cyclooxygenase-2 expression in normal human mesangial cells and kidneys of rats with diabetic nephropathy

Journal of Central South University (Medical Sciences)

Volumn 33, Issue 9, 2008, Pages 790-799

  Zhou, Qiao Ling ^a   Peng, Wei Sheng ^a   Yasumoto, Yuichiro ^b   Liu, Zhi Chun ^a   Yang, Jing Hua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase; Diabetic nephropathy; Losartan; Normal human mesangial cell

Indexed keywords

CYCLOOXYGENASE 2; LOSARTAN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; MALE; MESANGIUM CELL; PATHOLOGY; RANDOMIZATION; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; DIABETIC NEPHROPATHIES; HUMANS; LOSARTAN; MALE; MESANGIAL CELLS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 53649095475     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Chandrasekharan N V, Dai H, Roos K L, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression[J]. Proc Natl Acad Sci USA, 2002, 99 (21): 13926-13931.
2. Cheng H F, Wang C J, Moeckel G W, et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension[J]. Kidney Int, 2002, 62 (3): 929-939.
3. Wang J L, Cheng H F, Shappell S, et al. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats[J]. Kidney Int, 2000, 57 (6): 2334-2342.
4. Ritz E, Orth S R. Nephropathy in patients with type 2 diabetes mellitus[J]. N Engl J Med, 1999, 341 (15): 1127-1133.
5. Lewis E J, Hunsicker L G, Bain R P, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy[J]. N Engl J Med, 1993, 329 (20): 1456-1460.
6. Remuzzi A, Perico N, Amuchastegui C S, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes[J]. J Am Soc Nephrol, 1993, 4 (1): 40-49.
7. Parving H H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes[J]. N Engl J Med, 2001, 345 (12): 870-878.
8. Ots M, Machenzie H S, Tory J L. Effects of combination therapy with enapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass abation[J]. J Am Soc Nephrol, 1998, 9 (2): 224-230.
9. Murihead N, Feagan F, Mahon J. The effects of valsartan and captopril on reducing microalbuminuria in patients with 2 diabetes mellitus; a placebo-controlled trial[J]. Curr Ther Res, 1999, 60 (12): 650-660.
10. Cosenzi A, Bernobich E, Trevisan R. Nephroprotective effect of bosentan in diabetic rats[J]. J Cardiovasc Pharmacol, 2003, 42 (6): 752-756.
11. Okumura M, Imanishi M, Yamashita T, et al. Renal production of thromboxane and prostaglandins in a rat model of Type 2 diabetes[J]. Life Sci, 2000, 66 (5): 371-377.
12. Hirawa N, Uehara Y, Ikeda T, et al. Urinary prostaglandin D synthase (beta-trace) excretion increases in the early stage of diabetes mellitus[J]. Nephron, 2001, 87 (4): 321-327.
13. Hamano K, Totsuka Y, Ajitna M, et al. Blood, sugar control reverses the increase in urinary excretion of prostaglandin D synthase in diabetic patients[J]. Nephron, 2002, 92 (1): 77-85.
14. Mahadevan P, larkins R G, Fraser J R et al. Effect of prostaglandin E2 and hyaluronan on mesangial cell proliferation. A potential contribution to glomerular hypercellarity in diabetes[J]. Diabetes, 1996, 45 (1): 44-50.
15. Wolf G, Ziyadeh F N. Molecular mechanisms of diabetic renal hypertrophy[J]. Kidney Int, 1999, 56 (2): 393-405.
16. Umezono T, Toyoda M, Kato M, et al. Glomerular expression of CTGF, TGF-beta 1 and Type IV collagen in diabetic nephropathy[J]. J Nephrol, 2006, 19 (6): 751-757.
17. Osterby R, Tapia J, Nyberg G, et al. Renal structures in type 2 diabetic patients with elevated albumin excretion rate[J]. APMIS, 2001, 109 (11): 751-761.
18. Osterby R, Hartmann A, Nyengaard J R, et al. Development of renal structural lesions in type 1 diabetic patients with microalbuminuria. Observations by light microscopy in 8-year follow-up biopsies[J]. Virchows Arch, 2002, 440 (1): 94-101.
19. Jensen B L, Kurtz A. Differential regulation of renal cyclooxygenase mRNA by dietary salt intake[J]. Kidney Int, 1997, 52 (5): 1242-1249.
20. Wang J L, Cheng H F, Harris R C. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension[J]. Hypertension, 1999, 34 (1): 96-101.
21. Park I S, Kiyomoto H, Abboud S L, et al. Expression of transforming growth factor-[beta] and Type IV collagen in early streptozotocin-induced diabetes[J]. Diabetes, 1997, 46 (3): 473-480.
22. Sharma K, Ziyadeh F N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-[beta] as a key mediator[J]. Diabetes, 1995, 44 (10): 1139-1146.
23. Twigg S M, Cao Z, McLennan S V, et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine[J]. Endocrinology, 2002, 143 (9): 4907-4915.
24. Kelly D J, Gilbert R E, Cox A J, et al. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy[J]. J Am Soc Nephrol, 2001, 12 (10): 2098-2107.
25. Bohle A, Wehrmann M, Bogenschutz O, et al. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis[J]. Pathol Res Pract, 1999, 187 (2-3): 251-259.
26. Chen S, Hong S W, Iglesias-de la Cruz M C, et al. The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy[J]. Ren Fail, 2001, 23 (3-4): 471-481.
27. Chen S, Jim B, Ziyadeh F N. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up[J]. Semin Nephrol, 2003, 23 (6): 532-543.